Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Fabienne G. M. Smeets*, Paulien R. Liedorp, Marjolein van der Poel, Razvan L. Miclea, Ad A. M. Masclee, Marieke Pierik

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

2 Citations (Web of Science)

Abstract

Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

Original languageEnglish
Pages (from-to)1470-1473
Number of pages4
JournalJournal of Crohn's & Colitis
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Ustekinumab
  • lymphoma
  • Crohn's disease
  • INFLAMMATORY-BOWEL-DISEASE
  • MAINTENANCE THERAPY
  • TERM SAFETY
  • CANCER-RISK
  • INDUCTION

Cite this